Phase
Phase, Inc. develops a proprietary 3D printing platform (3DPDMS) for fabricating microfluidic devices and organ-on-a-chip models using PDMS and other biocompatible materials at commercial scale and high resolution.
- CEO / Founder
- Jeff Schultz
- Team Size
- 1-10
- Stage
- Early Stage
- Latest Round
- Grant
- Key Investors
- National Institutes of Health (NIH); National Science Foundation (NSF); North Carolina Biotechnology Center; One North Carolina Small Business Program
Technology & Products
Key Products
3DPDMS 3D printing platform; custom microfluidic device design and fabrication; organ-on-a-chip models (including blood-brain-barrier models); automated microfluidic device manufacturing service
Technological Advantage
Proprietary 3DPDMS technology enabling 3D printing of PDMS at commercial scale with biological-scale resolution; ability to integrate valves, sensors, and electrodes during printing; highly automated and reproducible process; backed by $3.5M+ in nondilutive federal and state grants.
Differentiation
Value Proposition
Phase enables rapid, automated, scalable 3D printing of PDMS microfluidic devices with integrated functional features (valves, sensors, electrodes) at biologically relevant resolution, replacing slow, manual cleanroom-based fabrication.
How They Differentiate
Phase's proprietary 3DPDMS technology is the only platform that 3D prints microfluidic devices using PDMS (the industry-standard biocompatible material) at commercial scale with resolution matching biological scale, while integrating valves, sensors, and electrodes during the printing process — capabilities not feasible with conventional microfabrication or existing 3D printing technologies.
Market & Competition
Target Customers
Biomedical researchers, pharmaceutical companies, organ-on-a-chip developers, drug discovery labs, and academic research institutions developing microfluidic devices for disease modeling and drug testing.
Industry Verticals
Biotech; Pharmaceuticals; Biomedical Research; Drug Discovery; Organ-on-a-chip
Competitors
Fluigent; Micronit; uFluidix; Dolomite Microfluidics
Growth & Milestones
Major Milestones
2020: Company founded; 2022: Received One North Carolina Small Business Program grant; 2023: Received NC Biotech Small Business Research Loan; 2024: Awarded $1.8M NIH grant for blood-brain-barrier organ-on-a-chip with Harvard, Georgia Tech, Virginia Tech; 2026: Awarded NSF STTR grant with George Mason University for automated microfluidic platform; Surpassed $3.5M in total nondilutive funding.
Notable Customers
Harvard Medical School (Massachusetts General Hospital); Georgia Tech; Virginia Tech; George Mason University